Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Company profile
Ticker
ZSANQ
Exchange
Website
CEO
Steven Lo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ZP Holdings Inc
SEC CIK
ZSANQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
19 Jul 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jun 22
8-K
Termination of a Material Definitive Agreement
2 Jun 22
8-K
Departure of Directors or Certain Officers
18 May 22
10-Q
2022 Q1
Quarterly report
13 May 22
8-K
Zosano Pharma Reports First Quarter 2022 Financial Results
13 May 22
8-K
Departure of Directors or Certain Officers
5 May 22
8-K
Zosano Pharma Provides Corporate Update
29 Apr 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
8-K
Zosano Pharma Announces Reverse Stock Split Effective Today
11 Apr 22
Transcripts
ZSANQ
Earnings call transcript
2019 Q3
14 Nov 19
ZSANQ
Earnings call transcript
2019 Q2
14 Aug 19
ZSANQ
Earnings call transcript
2019 Q1
14 May 19
ZSANQ
Earnings call transcript
2018 Q4
14 Mar 19
ZSANQ
Earnings call transcript
2018 Q3
14 Nov 18
ZSANQ
Earnings call transcript
2018 Q2
9 Aug 18
ZSANQ
Earnings call transcript
2018 Q1
15 May 18
ZSANQ
Earnings call transcript
2017 Q3
9 Nov 17
Latest ownership filings
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.98 mm | 13.98 mm | 13.98 mm | 13.98 mm | 13.98 mm | 13.98 mm |
Cash burn (monthly) | (no burn) | 1.11 mm | 11.14 mm | 4.75 mm | 2.85 mm | 2.39 mm |
Cash used (since last report) | n/a | 27.37 mm | 273.90 mm | 116.87 mm | 70.01 mm | 58.76 mm |
Cash remaining | n/a | -13.38 mm | -259.92 mm | -102.88 mm | -56.03 mm | -44.78 mm |
Runway (months of cash) | n/a | -12.0 | -23.3 | -21.7 | -19.7 | -18.7 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 5 |
Closed positions | 9 |
Increased positions | 9 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 2.69 mm |
Total shares | 11.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 5.15 mm | $1.16 mm |
Aisling Capital Management | 2.72 mm | $612.00 k |
BLK Blackrock | 2.05 mm | $462.00 k |
STT State Street | 436.34 k | $98.00 k |
Renaissance Technologies | 249.01 k | $56.00 k |
Telemetry Investments, L.L.C. | 210.00 k | $47.00 k |
NTRS Northern Trust | 199.50 k | $45.00 k |
BCS Barclays | 150.00 k | $34.00 k |
UBS UBS Group AG - Registered Shares | 144.67 k | $32.00 k |
C Citigroup | 124.70 k | $28.00 k |